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Background: Several anti-malarial drugs are associated with adverse cardiovascular effects. These effects may be
exacerbated when different anti-malarials are used in combination. There has been no report yet on the potential
cardiac effects of the combination artesunate-amodiaquine.
Methods: Electrocardiographic (ECG) intervals in Ghanaian children with uncomplicated malaria treated with
artesunate-amodiaquine (n=47), were compared with that of children treated with artemether-lumefantrine (n=30).
The ECG measurements were repeated one, two, three, seven and 28 days after treatment. The ECG intervals of
artesunate-amodiaquine treated subjects were correlated with plasma concentrations of desethylamodiaquine
(DEAQ), the main metabolite of amodiaquine.
Results: The mean ECG intervals were similar in both groups before treatment. After treatment (day 3), ECG
intervals changed significantly from baseline in all subjects, but there were no differences between the two
treatment groups. A significantly higher proportion of children treated with artesunate-amodiaquine developed
sinus bradycardia compared with artemether-lumefantrine treated subjects (7/47 vs 0/30; χ2 p=0.03). Subjects who
developed bradycardia were significantly older, and had higher DEAQ concentrations than those who did not
develop bradycardia. The proportion of subjects with QTc interval prolongations did not differ significantly between
the groups, and no relationship between prolonged QTc intervals and DEAQ levels were observed. No clinically
significant rhythm disturbances were observed in any of the subjects.
Conclusion: Artesunate-amodiaquine treatment resulted in a higher incidence of sinus bradycardia than
artemether-lumefantrine treatment in children with uncomplicated malaria, but no clinically significant rhythm
disturbances were induced by combining artesunate with amodiaquine. These findings, although reassuring, may
imply that non-amodiaquine based artemisinin combination therapy may be preferable for malaria treatment in
patients who are otherwise at risk of cardiac effects.
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Artesunate-amodiaquine combination is an efficacious
artemisinin combination therapy (ACT) regimen that
has been widely adopted for first-line treatment of un-
complicated malaria in many endemic countries [1-3].
There is limited information, however, on aspects of the
safety of this combination therapy regimen, particularly
on its potential cardiovascular effects.
Amodiaquine belongs to the 4-aminoquinoline class of
anti-malarials, and has previously been associated with
minor cardiac effects, including bradycardia, in adults
[4]. Amodiaquine is also structurally related to chloro-
quine, a 4-aminoquinoline that has significant cardiac
effects, including lethal cardiovascular toxicity in over-
dose [5,6].
The artemisinin derivatives on the other hand, are
among the safest anti-malarials known; however, earlier
studies in animals, especially of the oil-soluble deriva-
tives have linked these anti-malarials with cardiac
effects, including abnormalities in depolarization [7], or
suppression of cardiac conduction [8].
These reported cardiovascular effects of amodiaquine
or artemisinin or its derivatives are considered clinically
insignificant, but there is the possibility that these effects
could be potentiated when these anti-malarials are used
in combination: e g, overlapping therapy of mefloquine
and halofantrine has been shown to result in a QT inter-
val prolongation greater than that of either drug alone
[9,10], and the QT interval prolongation of quinine is
enhanced by prior administration of artemether-
lumefantrine [11].
These considerations make it important that poten-
tial cardiovascular effects of newly introduced anti-
malarials should to be evaluated in combination.
However, there have been no reports yet, on the po-
tential cardiac effects of the artesunate-amodiaquine
combination, in spite of the fact that other ACT regi-
mens that have been widely deployed for malaria
control in endemic areas, including artemether-
lumefantrine [12,13], dihydroartemisinin-piperaquine
[14,15], and artesunate-mefloquine [16], have all been
extensively evaluated for cardiotoxic potential.
This study reports the electrocardiographic (ECG)
changes in Ghanaian children with uncomplicated malaria
treated with artesunate-amodiaquine, or artemether-
lumefantrine. The ECG changes in the artesunate-
amodiaquine treated children have been correlated with
plasma concentrations of desethylamodiaquine (DEAQ),
the main, active metabolite of amodiaquine.
Methods
Study site and patients
The study was part of a clinical trial that was conducted
to evaluate the safety and efficacy of artesunate-amodiaquine and artemether-lumefantrine as potential
ACT regimens for first-line treatment of uncomplicated
malaria in Ghana. Approval for the study was granted by
the Ethics and Protocol Review Committee of the Uni-
versity of Ghana Medical School, and written, informed
consent was obtained from the accompanying parent or
guardian of all enrolled children. The full description of
the study site and results of the trial have been previ-
ously reported [1]. Briefly, enrolled children aged 0.5–14
years with uncomplicated malaria were treated with: i)
artesunate (PlasmotrimW, Mepha; Switzerland), 4 mg/kg
body weight as a single daily dose + amodiaquine
(CamoquineW, Pfizer; Dakar, Senegal), 10 mg/kg body
weight, single daily dose, for three days; or, ii)
artemether-lumefantrine (CoartemW, Novartis Pharma
AG, Basel, Switzerland; 20 mg artemether and 120 mg
lumefantrine), given at zero and eight hours on the
first day and then twice daily for the two subsequent
days according to body weight: 9–14 kg, one tablet/
dose; 15–24 kg, two tablets/dose; 25–34 kg, three
tablets/dose; 35 kg and over, four tablets/dose.
After enrolment, a full clinical examination was done,
and key demographic and clinical information were
recorded on a standard questionnaire. Venous blood was
collected into EDTA and heparinized tubes for the de-
termination of parasite count, haematological and bio-
chemical investigations, and for amodiaquine and
plasma drug (amodiaquine and metabolites; desethyla-
modiaquine, bis-desethylamodiaquine) concentration
measurements.Electrocardiography (ECG)
A standard 12-lead ECG (Esaote P80, Firenze, Italy) was
performed at a paper speed of 50 mm/s and a sensitivity
of 10 mm/mV. The ECG was done at baseline (0 h), 24,
and 48 hours later, and then on days 3, 7 and 28 in chil-
dren who were able to cooperate with the testing. The
24 and 48 hour times were chosen to minimize the pos-
sible effect of circadian variation on ECG indices [17],
and the day 3 ECG approximates the time of expected
high plasma concentrations of DEAQ. The ECGs were
evaluated with respect to rate, rhythm, QT interval, QRS
interval, as well as qualitative changes in T and U wave
morphology. The PR interval was measured from the
onset of the P wave to that of the R wave, the QT inter-
vals were measured from the onset of the QRS to the
end of the T wave (defined as return of the terminal
limb to baseline), and the RR interval was measured as
the time between the peaks of two QRS complexes. The
QT interval was measured in lead II or in lead III or V5
in case of artefacts (low T wave amplitude) in lead II.
The corrected QT interval (QTc) was calculated, using i)
Hodges’ formula: (QTcH) = QT + 1.75 (ventricular rate -
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0.5); and iii)
Fridericia’s formula: (QTcF) = QT/RR
0.3).
Laboratory investigations
Haemoglobin concentration and total white blood cell
count (WBC) were determined by means of an auto-
mated analyzer (Cell Dyn, Abbott Laboratories, USA).
Thick and thin blood films were stained with Giemsa
and read under 100X magnification. Parasite density was
determined by counting the number of asexual parasites
per 200 WBCs and multiplied by the measured WBC
count to obtain a count per microlitre.
Plasma amodiaquine and metabolite concentrations
Plasma concentrations of amodiaquine and its main
metabolites were measured from samples taken before
(on day 0) or after (on days 3, 7, and 28) ECG measure-
ments, using a reverse-phase high performance liquid
chromatographic method with ultraviolet detection. The
recovery for the drugs in plasma was 81%, 94% and 96%
for bis-desethylamodiaquine, desethylamodiaquine, and
amodiaquine, respectively.
Data analysis
The data were analysed using Stata™ (version 10, Stata
Corp, Texas, USA). Continuous data were analysed,
using the paired or unpaired T tests for normally distrib-
uted data, and the Mann–Whitney U tests for non-
normally distributed data, as appropriate. Categorical
data were analysed using the Chi square or Fischer exact
test, with Yates correction as appropriate. Categorical
analyses of outlying QTc values were done to ascertain
the proportion of patients with: i) absolute QTc intervals
of >30 ms, or 60 ms from baseline, and ii) QTc increases
>25% from baseline, and absolute QTc intervals >440
ms. The relationship(s) between specified variables wasTable 1 Baseline characteristics
Artemether-lumefantrin
*Age (yrs) 8.00 (4–12)
Weight (Kg) 24.00 (8.70)
Parasite density (/μL) 76545 (68726)
Haemoglobin (g/dL) 12.22 (1.59)
WBC (x103/L) 8.42 (3.43)
Rate (min) 114.73 (19.26)
PR (ms) 124.00 (16.10)
QT (ms) 296.00 (24.86)
QTcH (ms) 391.80 (24.40)
QTcB (ms) 406.03 (27.84)
QTcF (ms) 365.16 (23.11)
Data are means and standard deviations except *age (range); P > 0.05 all comparisoanalysed using Spearman’s correlation or by linear re-
gression. P values <0.05 were considered significant.
Results
Comparisons of mean ECG interval changes
The baseline demographic and selected clinical para-
meters on admission (day 0) for the two treatment
groups were similar (Table 1). There was a difference in
the mean ECG parameters before (day 0) and immedi-
ately after (day 3) treatment, within each of the treat-
ment groups (p<0.01). However, there were no
significant differences between the ECG intervals in the
two groups on days 3, or day 7 (Table 2). The proportion
of subjects with bradycardia (defined as a ventricular
rate below the normal for age), was significantly higher
(p=0.03) in the artesunate-amodiaquine group (14.8%;
7/47), compared with the artemether-lumefantrine group
(0/30). The mean age of subjects who developed brady-
cardia (11.8 years) was significantly higher (p<0.001)
than those who did not (6.3 years). Selected characteris-
tics of subjects who developed bradycardia are shown
(Table 3). The proportion of subjects with QTc interval
change greater than 30 ms from baseline was also higher
in the artesunate-amodiaquine group (31.9%; 15/47)
compared with the artemether-lumefantrine group (20%;
6/30), but the difference was not statistically significant
(OR, 1.9, 95% CI, 0.6-6.4, p=0.25), and this was not con-
fined to older age groups. Selected characteristics of sub-
jects with QTc increase more than 60 ms from baseline
are shown (Table 4).
DEAQ plasma concentrations and ECG changes
(amodiaquine-based treatment groups)
Plasma DEAQ concentrations were available for 36 sub-
jects in the artesunate-amodiaquine group. The mean
DEAQ concentrations were, 194.51 (range, 0–375 ng/ml).













Table 2 ECG parameters [means, (SD)] on days 3 (upper panels) and day 7 (lower panels) for the two groups
Artemether-lumefantrine (n=30) Artesunate-amodiaquine (n=47)
Rate (min) 86.10 (14.89) 80.06 (15.76)
90.11 (15.99) 90.11 (22.00)
PR (ms) 126.90 (18.73) 134.47 (21.14)
134.29 (19.52) 130.91 (18.02)
QT (ms) 330.67 (29.59) 339.57 (29.92)
321.43 (33.52) 323.56 (30.54)
QTcH (ms) 376.47 (22.66) 374.81 (21.77)
374.18 (19.19) 372.09 (21.94)
QTcB (ms) 392.71 (27.99) 388.04 (26.70)
389.36 (23.56) 387.67 (27.20)
QTcF (ms) 370.54 (24.72) 370.77 (22.20)
364.90 (22.85) 364.71 (25.040
QTcB =Bazett’s corrected QTc; QTcF =Fridericia’s corrected QTc; QTcH = Hodges’ corrected QTc.
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cantly higher (p=0.01), than the mean DEAQ concen-
tration of those who did not (165.2 ng/ml).
The correlation between DEAQ concentrations and
day 3 QTc intervals, or between DEAQ concentrations
and QTc change (between day 0 and day 3) was only
weakly negative (data not shown). There was no marked
trend between a plot of mean QTc on day 3 and plasma
DEAQ concentrations (figure not shown).
Comparisons based on the various QT correction
formulae
The number of subjects with QTc interval prolongation
>30 ms from baseline identified by the various correc-
tion formulae were: Bazett’s, (n=23); Fridericia’s, (n=21);
and Hodges, (n=10). The corresponding number of sub-
jects with QTc interval prolongation >60 ms from base-
line identified were: Bazett’s, (n=4); Fridericia’s, (n=6),
and Hodges, (n=0). The correlation between the QTc
intervals, corrected using any of the three formulae, and
RR intervals were only weakly negative (Table 5). A uni-
variate linear regression model identified day 0 QTc
intervals as the only significant predictor of the day 3
QTc interval.Table 3 Selected characteristics of subjects who developed b








AR=apex rate; DEAQ=desethylamodiaquine; NA=Not available; A-A=artesunate-amoOther ECG changes
The pre-treatment ECG of a 12 year-old girl (artesunate-
amodiaquine-treated) showed features of right QRS axis
deviation. This subject developed bradycardia on day 3
(ventricular rates were, 109, 57, 68, 71, on days 0, 3, 7
and 28, respectively but, there were no associated ad-
verse cardiovascular effects.
Discussion
The importance of evaluating potential cardiotoxic
effects of newly introduced anti-malarial drugs has been
highlighted with discovery of the cardiotoxicity of halo-
fantrine after its registration and introduction into clin-
ical practice. Apart from halofantrine, anti-malarials,
such as quinine and quinidine, have also been associated
with cardiotoxicity, mainly clinically significant delays in
ventricular repolarization, which is reflected on the ECG
as prolongation of the QT interval. The findings of rela-
tively short pre-treatment QT intervals in this study is
consistent with reports from ECG studies in African
children with uncomplicated malaria [18], and are pre-
sumed to result from differences in autonomic state be-
tween acute illness and recovery. It is suggested that the
increased sympathetic tone, blunted autonomic posturalradycardia (HR < normal for age)









Table 4 Subjects with QTc >60 ms from baseline based on different QT correction formulae
Age (yrs) Sex Drug QTc day 0 (ms) QTc day 3 (ms) Δ QTc(day3-day0) DEAQ (ng/ml)
3.5 Male A-A 361B 413B 52 109
315F 379F 64
373H 390H 17
5.5 Female A-A 353B 399B 46 162
310F 386F 76
363H 385H 22
6.0 Female A-A 404B 464B 60 0
357F 426F 69
394H 430H 36
6.5 Male A-A 361B 443B 82 241
315F 397F 82
373H 416H 43
9.0 Male A-L 366B 443B 77 NA
335F 413F 78
355H 414H 59
10.0 Female A-L 387B 450B 63 NA
347F 418F 71
376H 419H 43
B=Bazett’s QTc; F=Fridericia’s QTC; H=Hodges QTc; ΔQTc =change in QTc; A-A=artesunate-amodiaquine; A-L=artemether-lumefantrine;
DEAQ=desethylamodiaquine concentration; NA=Not applicable.
Table 5 Correlation between QTc and RR, using the various correction formulae
Hodges formula QTC RR Pearson’s correlation coefficient
QTC vs RR day 0 (A-L) 391.80 (24.40) 0.54 (0.09) −0.675
QTC vs RR day 3 (A-L) 376.47 (22.66) 0.72 (0.12) −0.256
QTC vs RR day 7 (A-L) 374.18 (19.19) 0.69 (0.14) 0.065
QTC vs RR day 0 (A-A) 390.28 (26.59) 0.52 (0.10) −0.252
QTC vs RR day 3 (A-A) 374.81 (21.77) 0.78 (0.15) −0.239
QTC vs RR day 7 (A-A) 372.09 (21.94) 0.70 (0.12) 0.458
Bazett’s formula QTc RR Correlation coefficient
QTCb vs RR day 0 (A-L) 406.03 (27.84) 0.54 (0.09) −0.373
QTCb vs RR day 3 (A-L) 392.71 (27.99) 0.72 (0.12) −0.366
QTCb vs RR day 7 (A-L) 389.36 (23.56) 0.69 (0.14) −0.14
QTCb vs RR day 0 (A-A) 399.57 (33.44) 0.52 (0.10) 0.097
QTCb vs RR day 3 (A-A) 388.04 (26.70) 0.78 (0.15) −0.492
QTCb vs RR day 7 (A-A) 387.67 (27.20) 0.70 (0.12) −0.283
Fridericia’s formula QTc RR Correlation coefficient
QTCf vs RR day 0 (A-L) 365.16 (23.11) 0.54 (0.09) 0.026
QTCf vs RR day 3 (A-L) 370.54 (24.72) 0.72 (0.12) 0.032
QTCf vs RR day 7 (A-L) 364.90 (22.85) 0.69 (0.14) 0.364
QTCf vs RR day 0 (A-A) 357.42 (33.27) 0.52 (0.10) 0.419
QTCf vs RR day 3 (A-A) 370.77 (22.20) 0.78 (0.15) −0.023
QTCf vs RR day 7 (A-A) 364.71 (25.04) 0.70 (0.12) 0.116
QTcb =Bazett’s corrected QTc; QTcf =Fridericia’s corrected QTc; QTch = Hodges’ corrected QTc; A-A=artesunate-amodiaquine; A-L=artemether-lumefantrine; RR=RR
interval.
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accelerates cardiac conduction, leading to a shortening
of the QT interval. These changes, when reversed during
convalescence then result in QT interval prolongation
[reviewed in [19].
The observed difference in bradycardia occurrence
between the amodiaquine-artesunate and artemether-
lumefantrine groups is likely a reflection of a true
difference between the treatment regimens. This is be-
cause the major differences between childhood and
adult ECG (e.g., faster ventricular rate that slows with
age, dimunition of right ventricular dominance, left-
ward shift of QRS axis with age) are related to matur-
ational changes that may not necessarily impact
directly on conduction. Furthermore, bradycardia oc-
curred mostly in older children, similar to the previ-
ously reported high bradycardia incidence in
amodiaquine-treated adults [4,20], and also consistent
with findings from animal studies that showed that
amodiaquine slows cardiac conduction [21,22]. Since
alterations in cardiac conduction pathways are an im-
portant mechanism for pro-arrhythmic events, and
bradycardia may by itself, precipitate long QT syn-
drome [23,24], the potential implications of artesunate-
amodiaquine associated bradycardia merits further
investigation.
The lack of association between plasma DEAQ levels
and QTc interval prolongation in the amodiaquine-
artesunate group could be due to lack of a consistent
effect of amodiaquine on cardiac repolarization. This
assertion is supported in part by the finding that base-
line QTc intervals were the sole predictor of post-
treatment QTc intervals. This lack of dose-related
association may also be due to the fact that these
effects of amodiaquine-based treatment differ from
that of anti-malarials such as halofantrine [12,25] or
quinine [26-28] whose cardiotoxic effects have been
shown to be clearly dose-dependent.
The mean QTc interval changes from baseline were
below the 25% increase beyond which such changes are
considered of clinical concern [29], and the proportion
of children with absolute QTc interval prolongation be-
yond 60 ms (a threshold that is considered significant
for evaluating potential cardiotoxicity of new drugs), was
higher in the artesunate-amodiaquine treatment group,
though the number of subjects with these changes were
low to allow meaningful statistical testing.
The Fridericia’s formula was as sensitive as the Bazett’s
formula in identifying prolonged QT intervals in this
study population. The utility of the Fridericia’s formula
for evaluating potential cardiac effects of anti-malarial
drugs in childhood studies could be further evaluated,
since this correction formula is less rate-dependent, and
other correction methods developed primarily for adultsmay not be applicable to childhood populations [30].
However, the weak correlation between the RR and QT
intervals, corrected using the various formulae suggests
that the different rate correction formulae had the
desired effect.
Assessing the effect of antimalarials on an ECG, when
used during the treatment of malaria could be proble-
matic. This is because disease-associated changes in
malaria confound QT interval measurements, and
comparison of ECG changes should be done at the
same heart rate, ideally in volunteers without intercur-
rent illness. The opportunities for such studies however,
are limited. Furthermore, any potential disease-drug
interactions would be impossible to detect in volunteer
populations. The findings from this study are therefore,
important not least because: i) there is paucity of
published data on the ECG effects of anti-malarials,
particularly in children, and ii) the artemether-
lumefantrine group provides an exceptionally good
reference standard, since this ACT regimen has been
extensively evaluated and shown not to have any sig-
nificant cardiotoxicity [12,13].
In conclusion, the standard ECG intervals of children
with uncomplicated malaria treated with artesunate-
amodiaquine or artemether-lumefantrine showed
changes that are consistent with those observed in acute
malaria. The higher incidence of sinus bradycardia in
artesunate-amodiaquine treated subjects may have
implications for concomitant use of this ACT with car-
diac drugs, or for treatment of patients at increased risk
of cardiac dysrhythmiae. The artesunate-amodiaquine
regimen appears safe in other patients in this limited
study, but further studies in a larger cohort are war-
ranted for conclusive evidence on safety.
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